Previous 10 | Next 10 |
2024-06-02 15:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-23 17:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-20 09:58:45 ET More on PTC Therapeutics PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts PTC Therapeutics, Inc. (PTCT) Q1 2024 Earnings Call Transcript PTC Therapeutics, Inc. (PTCT) Q4 2023 Earnings Call Transcript PTC Therapeuti...
2024-05-13 17:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-12 11:00:00 ET More on Acadia Pharma, BridgeBio Pharma, etc. ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript ACADIA Pharmaceuticals Inc. 2024 Q1 - Results - Earnings Call Presentation Rocket Pharmaceuticals: Cautiously Optimistic (Rating U...
2024-05-09 18:44:45 ET More on Catalyst Pharmaceuticals, Sarepta Therapeutics, etc. Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2024 Earnings Call Transcript Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript Sarepta Therapeutics: Growth Trajectory Alter...
2024-05-08 16:51:21 ET More on Regenxbio Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform REGENXBIO Inc. (RGNX) Q4 2023 Earnings Call Transcript Regenxbio Q1 2024 Earnings Preview Regenxbio raised to Buy at RBC on pivot to Duchen...
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights PR Newswire Company remains on track for its first BLA filing in 2024 and is accelerating progress toward pivotal trial initiation for Duchenne (H2 2024) and diabetic retinopathy (H1 202...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
2024-05-07 17:20:34 ET More on Regenxbio Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform REGENXBIO Inc. (RGNX) Q4 2023 Earnings Call Transcript Regenxbio raised to Buy at RBC on pivot to Duchenne Regenxbio stock jumps 13% on pos...
News, Short Squeeze, Breakout and More Instantly...
2024-07-04 04:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients PR Newswire Company to begin enrollment of patients aged 1-3 years Expects data from younger cohort to be part of pivotal plans and BLA filing for broad lab...
REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II PR Newswire Aligned with FDA on content of BLA and plans for submission: Submission of a rolling BLA using the accelerated approval...